MNOV MediciNova Inc.

-0.2  -2%
Previous Close 11.44
Open 11.36
Price To Book 6.24
Market Cap 470720781
Shares 41,879,073
Volume 75,741
Short Ratio 37.19
Av. Daily Volume 78,607

Drug Information

Drug catalyst information is displayed when you hover over the stage bar graph.

Phase 2b top-line data released October 28, 2017 at Joint ECTRIMS – ACTRIMS meeting. Primary endpoint met.
Progressive multiple sclerosis (progressive MS)
Phase 2 abstract presented at EASL April 13, 2018. Noted April 2, 2018 that trial has been terminated early due meeting one of two primary endpoints (data from second endpoint of cholesterol efflux capacity not released).
NASH (nonalcoholic steatohepatitis)
Phase 2 data released March 29, 2018 - primary endpoint not met.
Methamphetamine dependence
Phase 2a trial fully enrolled - noted July 30, 2018. Data due 2019.
Amyotrophic lateral sclerosis (ALS)
Phase 2/3 trial initiation announced August 6, 2018.
MN-166 (ibudilast)
Degenerative cervical myelopathy (DCM)

Latest News

  1. The Daily Biotech Pulse: MediciNova Gets Orphan-Drug Status, KemPharm To Offer Shares, Emergent Buys Vaccine Maker
  2. MediciNova Announces FDA Grants Orphan Drug Designation to MN-166 (ibudilast) for Glioblastoma
  3. MNOV: Positive FDA Feedback on ALS Phase 3 Plan…
  4. MediciNova Announces Positive FDA Feedback Regarding Phase 3 Plan for MN-166 (ibudilast) in ALS
  5. MediciNova to Present at the Ladenburg Thalmann 2018 Healthcare Conference in New York
  6. MediciNova to Attend the Morgan Stanley Global Healthcare Conference in New York
  7. MediciNova Announces the Publication of Results of the SPRINT-MS Phase 2b Trial of MN-166 (ibudilast) in Progressive MS in the New England Journal of Medicine
  8. National Institute on Alcohol Abuse and Alcoholism Awards R01 Research Grant to UCLA for Phase 2b Clinical Trial of MediciNova's MN-166 (ibudilast) in Alcohol Use Disorder
  9. Report: Exploring Fundamental Drivers Behind MediciNova, Dermira, FRP, BiondVax Pharmaceuticals, The Descartes Systems Group, and American Software — New Horizons, Emerging Trends, and Upcoming Developments
  10. MediciNova Announces Initiation of NIHR Grant-Funded Phase 2/3 Trial of MN-166 (ibudilast) for the Treatment of Degenerative Cervical Myelopathy in Collaboration with the University of Cambridge
  11. MediciNova Announces MN-166 (ibudilast) ALS Abstract Accepted for Presentation at the 29th International Symposium on ALS/MND in Glasgow, Scotland, UK
  12. MediciNova Announces Full Enrollment in ALS Biomarker Clinical Trial
  13. MNOV: Plenty of Cash to Advance Pipeline Forward
  14. MNOV: Encouraging Data from Subgroup Analysis of ALS Study
  15. When Will MediciNova Inc (NASDAQ:MNOV) Become Profitable?
  16. Want To Invest In MediciNova Inc (NASDAQ:MNOV)? Here’s How It Performed Lately